OTC · AMPE
Ampio Pharmaceuticals, Inc.
$0.18$0.00 (0.0%)
Ampio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.55% below the high.
Loading market information…
OTC · RGMP · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Regnum Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.18$0.00 (0.0%)
Ampio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.55% below the high.
$0.00$0.00 (0.0%)
IR Biosciences Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
GlobeStar Therapeutics Corporation: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
GB Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.98% below the high.
$0.00+$0.00 (+500.0%)
Scorpius Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
$0.00$0.00 (0.0%)
Golden Developing Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
Bioasis Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Nexien BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.17% below the high.
